{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Muscle+Invasive+Bladder+Urothelial+Carcinoma&page=2",
    "query": {
      "condition": "Muscle Invasive Bladder Urothelial Carcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Muscle+Invasive+Bladder+Urothelial+Carcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:11:25.227Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06605404",
      "title": "Pan-tumor MRD Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma",
        "Esophageal Cancer",
        "Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma",
        "Melanoma (Skin Cancer)",
        "NSCLC (Non-small Cell Lung Cancer)",
        "Pancreatic (Exocrine Only)",
        "Mix of Solid Tumors (MOST)"
      ],
      "interventions": [
        {
          "name": "blood and tissue samples",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "blood and tissue samples",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Paradigm Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1350,
      "start_date": "2025-01-08",
      "completion_date": "2032-04",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-05-22T03:11:25.227Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Maumee, Ohio",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Maumee",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06605404"
    },
    {
      "nct_id": "NCT05833867",
      "title": "Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Localized Muscle Invasive Bladder Urothelial Carcinoma",
        "Muscle-Invasive Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sacituzumab govitecan",
          "type": "DRUG"
        },
        {
          "name": "Adaptive Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Shilpa Gupta, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-04-01",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-05-22T03:11:25.227Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05833867"
    },
    {
      "nct_id": "NCT05742867",
      "title": "A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2023-05-31",
      "completion_date": "2024-07-10",
      "has_results": false,
      "last_update_posted_date": "2025-01-23",
      "last_synced_at": "2026-05-22T03:11:25.227Z",
      "location_count": 1,
      "location_summary": "Morrisville, North Carolina",
      "locations": [
        {
          "city": "Morrisville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05742867"
    },
    {
      "nct_id": "NCT04688931",
      "title": "A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "UGN-102",
          "type": "DRUG"
        },
        {
          "name": "TURBT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 282,
      "start_date": "2021-02-19",
      "completion_date": "2023-03-17",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-05-22T03:11:25.227Z",
      "location_count": 33,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04688931"
    },
    {
      "nct_id": "NCT03518320",
      "title": "Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer TNM Staging Primary Tumor (T) T2",
        "Bladder Cancer TNM Staging Primary Tumor (T) T2A",
        "Bladder Cancer TNM Staging Primary Tumor (T) T2B",
        "Bladder Cancer TNM Staging Primary Tumor (T) T3",
        "Bladder Cancer TNM Staging Primary Tumor (T) T3A",
        "Bladder Cancer TNM Staging Primary Tumor (T) T3B",
        "Bladder Cancer TNM Staging Regional Lymph Node (N) N0",
        "Bladder Cancer TNM Staging Regional Lymph Node (N) N1",
        "Bladder Cancer TNM Staging Distant Metastasis (M) M0"
      ],
      "interventions": [
        {
          "name": "Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab Injection [Opdivo]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taris Biomedical LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2019-01-02",
      "completion_date": "2019-12-11",
      "has_results": false,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-05-22T03:11:25.227Z",
      "location_count": 6,
      "location_summary": "Hinsdale, Illinois • Rochester, New York • Durham, North Carolina + 3 more",
      "locations": [
        {
          "city": "Hinsdale",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03518320"
    },
    {
      "nct_id": "NCT04586244",
      "title": "An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "retifanlimab",
          "type": "DRUG"
        },
        {
          "name": "epacadostat",
          "type": "DRUG"
        },
        {
          "name": "INCAGN02385",
          "type": "DRUG"
        },
        {
          "name": "INCAGN02390",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-01-14",
      "completion_date": "2024-01-29",
      "has_results": true,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-05-22T03:11:25.227Z",
      "location_count": 4,
      "location_summary": "Iowa City, Iowa • Cincinnati, Ohio • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04586244"
    },
    {
      "nct_id": "NCT00794950",
      "title": "Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urinary Tract Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2009-01",
      "completion_date": "2016-08-22",
      "has_results": true,
      "last_update_posted_date": "2019-09-23",
      "last_synced_at": "2026-05-22T03:11:25.227Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00794950"
    },
    {
      "nct_id": "NCT03288545",
      "title": "A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Transitional Cell",
        "Urinary Bladder Neoplasms",
        "Urologic Neoplasms",
        "Renal Pelvis Neoplasms",
        "Urothelial Cancer",
        "Ureteral Neoplasms",
        "Urethral Neoplasms"
      ],
      "interventions": [
        {
          "name": "enfortumab vedotin (EV)",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 348,
      "start_date": "2017-10-11",
      "completion_date": "2026-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-05-22T03:11:25.227Z",
      "location_count": 83,
      "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 75 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03288545"
    },
    {
      "nct_id": "NCT03473730",
      "title": "Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Bladder Urothelial Carcinoma",
        "Clear Cell Renal Cell Carcinoma",
        "Malignant Urinary System Neoplasm",
        "Metastatic Kidney Carcinoma",
        "Stage IV Renal Cell Cancer AJCC V8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Daratumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Metastasectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Nephrectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2018-05-29",
      "completion_date": "2025-01-27",
      "has_results": false,
      "last_update_posted_date": "2025-01-30",
      "last_synced_at": "2026-05-22T03:11:25.227Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03473730"
    },
    {
      "nct_id": "NCT05483868",
      "title": "A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-muscle-invasive Bladder Cancer",
        "NMIBC",
        "Non-Muscle Invasive Bladder Carcinoma",
        "Non-Muscle Invasive Bladder Neoplasms",
        "Non-Muscle Invasive Bladder Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "AU-011",
          "type": "DRUG"
        },
        {
          "name": "AU-011 in Combination with Medical Laser Adminstration",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AU-011 in Combination with Medical Laser Administration",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Aura Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2022-09-26",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-22T03:11:25.227Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Santa Monica, California + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05483868"
    }
  ]
}